title: Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients.
abstract: BACKGROUND
  The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.
  
  
  OBJECTIVE
  To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.
  
  
  METHODS
  Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).
  
  
  RESULTS
  Seropositive patients were found to be predominantly female (p < 0.0003), to more often have signs of co-existing autoimmunity (p < 0.00001), and to experience more severe clinical attacks. A visual acuity of ≤ 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p < 0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ≤ 2 more frequent, in particular if patients met the 2006 revised criteria (p < 0.005, p < 0.006 and p < 0.01, respectively), the total spinal cord lesion load was higher (p < 0.006), and lesions ≥ 6 vertebral segments as well as entire spinal cord involvement more frequent (p < 0.003 and p < 0.043). By contrast, bilateral ON at onset was more common in seronegatives (p < 0.007), as was simultaneous ON and myelitis (p < 0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p < 0.029). The course of disease was more often monophasic in seronegatives (p < 0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p < 0.002 and p < 0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.
  
  
  CONCLUSIONS
  This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
authors.affiliation: Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
authors.forename: Sven
authors.initials: S
authors.lastname: Jarius
authors.forename: Klemens
authors.initials: K
authors.lastname: Ruprecht
authors.forename: Brigitte
authors.initials: B
authors.lastname: Wildemann
authors.forename: Tania
authors.initials: T
authors.lastname: Kuempfel
authors.forename: Marius
authors.initials: M
authors.lastname: Ringelstein
authors.forename: Christian
authors.initials: C
authors.lastname: Geis
authors.forename: Ingo
authors.initials: I
authors.lastname: Kleiter
authors.forename: Christoph
authors.initials: C
authors.lastname: Kleinschnitz
authors.forename: Achim
authors.initials: A
authors.lastname: Berthele
authors.forename: Johannes
authors.initials: J
authors.lastname: Brettschneider
authors.forename: Kerstin
authors.initials: K
authors.lastname: Hellwig
authors.forename: Bernhard
authors.initials: B
authors.lastname: Hemmer
authors.forename: Ralf A
authors.initials: RA
authors.lastname: Linker
authors.forename: Florian
authors.initials: F
authors.lastname: Lauda
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Mayer
authors.forename: Hayrettin
authors.initials: H
authors.lastname: Tumani
authors.forename: Arthur
authors.initials: A
authors.lastname: Melms
authors.forename: Corinna
authors.initials: C
authors.lastname: Trebst
authors.forename: Martin
authors.initials: M
authors.lastname: Stangel
authors.forename: Martin
authors.initials: M
authors.lastname: Marziniak
authors.forename: Frank
authors.initials: F
authors.lastname: Hoffmann
authors.forename: Sven
authors.initials: S
authors.lastname: Schippling
authors.forename: Jürgen H
authors.initials: JH
authors.lastname: Faiss
authors.forename: Oliver
authors.initials: O
authors.lastname: Neuhaus
authors.forename: Barbara
authors.initials: B
authors.lastname: Ettrich
authors.forename: Christian
authors.initials: C
authors.lastname: Zentner
authors.forename: Kersten
authors.initials: K
authors.lastname: Guthke
authors.forename: Ulrich
authors.initials: U
authors.lastname: Hofstadt-van Oy
authors.forename: Reinhard
authors.initials: R
authors.lastname: Reuss
authors.forename: Hannah
authors.initials: H
authors.lastname: Pellkofer
authors.forename: Ulf
authors.initials: U
authors.lastname: Ziemann
authors.forename: Peter
authors.initials: P
authors.lastname: Kern
authors.forename: Klaus P
authors.initials: KP
authors.lastname: Wandinger
authors.forename: Florian Then
authors.initials: FT
authors.lastname: Bergh
authors.forename: Tobias
authors.initials: T
authors.lastname: Boettcher
authors.forename: Stefan
authors.initials: S
authors.lastname: Langel
authors.forename: Martin
authors.initials: M
authors.lastname: Liebetrau
authors.forename: Paulus S
authors.initials: PS
authors.lastname: Rommer
authors.forename: Sabine
authors.initials: S
authors.lastname: Niehaus
authors.forename: Christoph
authors.initials: C
authors.lastname: Münch
authors.forename: Alexander
authors.initials: A
authors.lastname: Winkelmann
authors.forename: Uwe K
authors.initials: UK
authors.lastname: Zettl U
authors.forename: Imke
authors.initials: I
authors.lastname: Metz
authors.forename: Christian
authors.initials: C
authors.lastname: Veauthier
authors.forename: Jörn P
authors.initials: JP
authors.lastname: Sieb
authors.forename: Christian
authors.initials: C
authors.lastname: Wilke
authors.forename: Hans P
authors.initials: HP
authors.lastname: Hartung
authors.forename: Orhan
authors.initials: O
authors.lastname: Aktas
authors.forename: Friedemann
authors.initials: F
authors.lastname: Paul
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood*; D051401:Aquaporin 4 / Q000276:immunology*; D001933:Brain Stem / Q000473:pathology; D015331:Cohort Studies; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009471:Neuromyelitis Optica / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D043025:Oligoclonal Bands / Q000134:cerebrospinal fluid; D012008:Recurrence; D012189:Retrospective Studies; D013223:Statistics as Topic; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: C496030:AQP4 protein, human; D000906:Antibodies; D051401:Aquaporin 4; D043025:Oligoclonal Bands; D008775:Methylprednisolone